DS-1001b

DRUG2 trials

Sponsors

Daiichi Sankyo, Daiichi Sankyo Co., Ltd.

Conditions

GliomaWHO Grade II Glioma

Phase 1

Study of DS-1001b in Patients With Gene IDH1-Mutated Gliomas

CompletedNCT03030066

Daiichi SankyoGlioma

Start: 2017-01-19End: 2026-07-16Updated: 2026-07-28

Phase 2

A Study of DS-1001b in Patients With Chemotherapy- and Radiotherapy-Naive IDH1 Mutated WHO Grade II Glioma

Active, not recruitingNCT04458272

Daiichi Sankyo Co., Ltd.WHO Grade II Glioma

Start: 2020-07-08End: 2026-08-31Target: 25Updated: 2026-03-20

Related Papers

Phase II study of safusidenib erbumine in patients with chemotherapy- and radiotherapy-naïve isocitrate dehydrogenase 1-mutated WHO grade 2 gliomas.

2025-11-08

CTNI-19. PHASE 2, MULTICENTER, RANDOMIZED CLINICAL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SAFUSIDENIB IN PATIENTS WITH HIGH-GRADE ISOCITRATE DEHYDROGENASE 1 (IDH1)-MUTANT GLIOMA

Neuro-Oncology2025-11-01

The first-in-human phase I study of a brain-penetrant mutant IDH1 inhibitor DS-1001 in patients with recurrent or progressive IDH1-mutant gliomas

Neuro-Oncology2022-06-2076 citations

ACT-14 A FIRST-IN-HUMAN STUDY OF MUTANT IDH1 INHIBITOR DS-1001B IN PATIENTS WITH RECURRENT GLIOMAS

Neuro-Oncology Advances2019-12-01

Phase I study of a brain penetrant mutant IDH1 inhibitor DS-1001b in patients with recurrent or progressive <i>IDH1</i> mutant gliomas.

Journal of Clinical Oncology2019-05-2023 citations